Clinical trial · Interventional
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
Ma-Spore ALL 2010 Study
NCT02894645CI-TRIAL-00024102unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall objective of this study is to continue to improve the cure rate of childhood acute lymphoblastic leukemia (ALL) in Singapore and Malaysia in the context of a multi-centre cooperative trial using a risk-stratified therapy based primarily on early response to therapy utilizing a simplified minimal residual disease (MRD-lite) platform.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia (ALL) | Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (13)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 6-Mercaptopurine | Drug | Mercaptopurine | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Fludarabine | Drug | Fludarabine | ALIAS |
| Imatinib | Drug | Imatinib | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Standard Risk (SR)
- interventionNames
- Drug: Prednisolone
- Drug: Dexamethasone
- Drug: L-Asparaginase
- Drug: Vincristine
- Drug: Methotrexate
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: 6-Mercaptopurine
- Drug: Thioguanine
- type
- OTHER
- label
- Intermediate Risk (IR)
- interventionNames
- Drug: Prednisolone
- Drug: Dexamethasone
- Drug: L-Asparaginase
- Drug: Vincristine
- Drug: Methotrexate
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: 6-Mercaptopurine
- Drug: Thioguanine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed diagnosis of non-Burkitt B-lineage ALL 2. 1 to 17 years of age (before 18th birthday) 3. Renal function within normal range for age 4. Liver function within normal range for age 5. Able to participate in the full 2 years of treatment Exclusion Criteria: 1. Age less than one year or age greater than/equals to 18 years 2. Previous treatment with cytotoxic agents or high-dose steroids 3. Mixed phenotype acute leukemia (MPAL) 4. ALL as secondary malignancy 5. Abnormal renal or liver function 6. Doubtful compliance or unable to afford full course of therapy
References
Publications (2)
- DERIVEDAriffin H, Chiew EKH, Oh BLZ, Lee SHR, Lim EH, Kham SKY, Abdullah WA, Chan LL, Foo KM, Lam JCM, Chan YH, Lin HP, Quah TC, Tan AM, Yeoh AEJ. Anthracycline-Free Protocol for Favorable-Risk Childhood ALL: A Noninferiority Comparison Between Malaysia-Singapore ALL 2003 and ALL 2010 Studies. J Clin Oncol. 2023 Jul 10;41(20):3642-3651. doi: 10.1200/JCO.22.02347. Epub 2023 Jun 5. PMID 37276496
- DERIVEDYeoh AEJ, Lu Y, Chin WHN, Chiew EKH, Lim EH, Li Z, Kham SKY, Chan YH, Abdullah WA, Lin HP, Chan LL, Lam JCM, Tan PL, Quah TC, Tan AM, Ariffin H. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study. J Clin Oncol. 2018 Sep 10;36(26):2726-2735. doi: 10.1200/JCO.2018.78.3050. Epub 2018 Jul 25. PMID 30044693